200107430-1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02050 A2

(51) International Patent Classification[7]: A61N

(21) International Application Number: PCT/US00/18576

(22) International Filing Date: 6 July 2000 (06.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/348,592 6 July 1999 (06.07.1999) US

(71) Applicant: THE RXFILES.NET CORPORATION [US/US]; 347 South Tamiami Trail, P.O. Box 427, Nokomis, FL 34275 (US).

(72) Inventor: MCMICHAEL, John; 2465 Dogwood Drive, Wexford, PA 15090 (US).


(74) Agents: WEINER, Irving, M. et al.; Weiner & Burt, P.C., P.O. Box 186, Harrisville, MI 48740 (US).

(81) Designated States *(national)*: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHOD AND SYSTEM FOR USE IN TREATING A PATIENT WITH ANY DRUG TO OPTIMIZE THERAPY AND PREVENT AN ADVERSE DRUG RESPONSE



IPD.
1 appln (change of name See 18/306)
(change of address See PF 23 of 24/12/01)
1 INV.
IPC : A61B 19/00
IPER 5/2/01

(57) Abstract: A method and system for use in treating a patient receiving any drug to optimize therapy and to prevent an adverse drug response. This system employs surrogate markers or indicators, including blood levels of drug, to determine the next required dose for a patient. Because the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of a drug's action. Given the effectiveness of the drug's action, relative to the surrogate markers, a change in drug dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of a drug dose change based on the surrogate markers.

WO 01/02050 A2

Published:
— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.